Skip Nav Destination
Issues
Liver Cancer 2024, Vol. 13, No. 6
Editorial
Guidelines
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Keiichi Akahoshi; Junichi Shindoh; Minoru Tanabe; Shunichi Ariizumi; Susumu Eguchi; Yukiyasu Okamura; Masaki Kaibori; Shoji Kubo; Mitsuo Shimada; Akinobu Taketomi; Nobuyuki Takemura; Hiroaki Nagano; Masafumi Nakamura; Kiyoshi Hasegawa; Etsuro Hatano; Tomoharu Yoshizumi; Itaru Endo; Norihiro Kokudo
Liver Cancer (2024) 13 (6): 579–589.
https://doi.org/10.1159/000538627
Systematic Review
Research Article
Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma
Junichi Shindoh; Yusuke Kawamura; Keiichi Akahoshi; Masaru Matsumura; Satoshi Okubo; Norio Akuta; Minoru Tanabe; Norihiro Kokudo; Yoshiyuki Suzuki; Masaji Hashimoto
Liver Cancer (2024) 13 (6): 601–609.
https://doi.org/10.1159/000539381
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
Kyu-Pyo Kim; Kang Mo Kim; Baek-Yeol Ryoo; Won-Mook Choi; Won Chul Cha; Mira Kang; Dong Hyun Sinn; Myung Ji Goh; Do Young Kim; Min Ji Lee; Subin Lim; DongKyu Kim; Kyoungdae Baek; Joohyun Kim; Eui Jun Choi; Doik Lee; Jung-Ae Kim; Ki-Hun Kim
Liver Cancer (2024) 13 (6): 610–628.
https://doi.org/10.1159/000539724
Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis
Liver Cancer (2024) 13 (6): 643–654.
https://doi.org/10.1159/000539895
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
Richard S. Finn; Peter R. Galle; Michel Ducreux; Ann-Lii Cheng; Norelle Reilly; Alan Nicholas; Sairy Hernandez; Ning Ma; Philippe Merle; Riad Salem; Daneng Li; Valeriy Breder
Liver Cancer (2024) 13 (6): 655–668.
https://doi.org/10.1159/000539897
Letter to the Editor
Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
Liver Cancer (2024) 13 (6): 669–670.
https://doi.org/10.1159/000538580
Reply
Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
Liver Cancer (2024) 13 (6): 671–673.
https://doi.org/10.1159/000539205
Erratum
Erratum - Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Liver Cancer (2024) 13 (6): 674.
https://doi.org/10.1159/000538572
